Cargando…

APOE ε4 alters associations between docosahexaenoic acid and preclinical markers of Alzheimer’s disease

Docosahexaenoic acid is the main long-chain omega-3 polyunsaturated fatty acids in the brain and accounts for 30−40% of fatty acids in the grey matter of the human cortex. Although the influence of docosahexaenoic acid on memory function is widely researched, its association with brain volumes is un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coughlan, Gillian, Larsen, Ryan, Kim, Min, White, David, Gillings, Rachel, Irvine, Michael, Scholey, Andrew, Cohen, Neal, Legido-Quigley, Cristina, Hornberger, Michael, Minihane, Anne-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112902/ https://www.ncbi.nlm.nih.gov/pubmed/34007965 http://dx.doi.org/10.1093/braincomms/fcab085

Ejemplares similares

Test-retest reliability of spatial navigation in adults at-risk of Alzheimer’s disease
por: Coughlan, Gillian, et al.
Publicado: (2020)

Memory precision of object-location binding is unimpaired in APOE ε4-carriers with spatial navigation deficits
por: Gellersen, Helena M, et al.
Publicado: (2021)

APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease
por: Abdullah, Laila, et al.
Publicado: (2017)

Age‐dependent effects of APOE ε4 in preclinical Alzheimer's disease
por: Bonham, Luke W., et al.
Publicado: (2016)

A combined DHA-rich fish oil and cocoa flavanols intervention does not improve cognition or brain structure in older adults with memory complaints: results from the CANN randomized, controlled parallel-design study
por: Vauzour, David, et al.
Publicado: (2023)

Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort
por: Saleh, Rasha N. M., et al.
Publicado: (2023)

APOE ε4 Allele Is Associated with Elevated Levels of CSF VILIP-1 in Preclinical Alzheimer’s Disease
por: Wang, Lijun, et al.
Publicado: (2020)

Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months
por: Thai, Christine, et al.
Publicado: (2015)

APOE effects on regional tau in preclinical Alzheimer’s disease
por: Young, Christina B., et al.
Publicado: (2023)

Shared and unique effects of ApoEε4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer’s disease
por: Quan, Meina, et al.
Publicado: (2023)

Association of APOE Serum Levels and APOE ε2, ε3, and ε4 Alleles with Optic Neuritis
por: Momkute, Liucija, et al.
Publicado: (2022)

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
por: Lautner, Ronald, et al.
Publicado: (2017)

APOE ε4, an Alzheimer’s disease susceptibility allele, and smoking cessation
por: Ashare, Rebecca L., et al.
Publicado: (2012)

APOEε4 and risk of Alzheimer’s disease – time to move forward
por: Lefterov, Iliya, et al.
Publicado: (2023)

The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress
por: Irvine, Michael A., et al.
Publicado: (2018)

Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome
por: Arnold, Matthias, et al.
Publicado: (2020)

Astrocytic expression of the Alzheimer’s disease risk allele, ApoEε4, potentiates neuronal tau pathology in multiple preclinical models
por: Jablonski, Angela Marie, et al.
Publicado: (2021)

THE APOE-ε4 ALLELE AND AGE SYNERGISTICALLY DRIVE DISEASE PROGRESSION IN ALZHEIMER’S DISEASE
por: Kleineidam, Luca, et al.
Publicado: (2019)

Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer’s disease biomarkers
por: Kulminski, Alexander M., et al.
Publicado: (2022)

Evidence that an APOE ε4 'double whammy' increases risk for Alzheimer's disease
por: Caesar, Ina, et al.
Publicado: (2012)

Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer’s Disease
por: Mishra, Aarti, et al.
Publicado: (2018)

Bioenergetic and inflammatory systemic phenotypes in Alzheimer’s disease APOE ε4‐carriers
por: Wilkins, Heather M., et al.
Publicado: (2021)

Dissecting the Gene Dose-Effects of the APOE ε4 and ε2 Alleles on Hippocampal Volumes in Aging and Alzheimer’s Disease
por: Hostage, Christopher A., et al.
Publicado: (2013)

Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice
por: Pankiewicz, Joanna E, et al.
Publicado: (2014)

Identification of an APOE ε4–specific blood‐based molecular pathway for Alzheimer's disease risk
por: Tao, Qiushan, et al.
Publicado: (2023)

Vestibular contribution to path integration deficits in ‘at-genetic-risk’ for Alzheimer’s disease
por: Coughlan, Gillian, et al.
Publicado: (2023)

APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology
por: Talyansky, Seth, et al.
Publicado: (2023)

APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology
por: Talyansky, Seth, et al.
Publicado: (2023)

Association between an Alzheimer’s Disease-Related Index and APOE ε4 Gene Dose
por: Schraml, Frank, et al.
Publicado: (2013)

Alzheimer's disease genetic risk variants beyond APOE ε4 predict mortality
por: Mez, Jesse, et al.
Publicado: (2017)

Rate of brain aging and APOE ε4 are synergistic risk factors for Alzheimer’s disease
por: Glorioso, Christin A, et al.
Publicado: (2019)

Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
por: Baek, Min Seok, et al.
Publicado: (2020)

APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia
por: Mirza, Saira Saeed, et al.
Publicado: (2019)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
por: Konijnenberg, Elles, et al.
Publicado: (2020)

Differences in plasma metabolites related to Alzheimer's disease, APOE ε4 status, and ethnicity
por: Vardarajan, Badri, et al.
Publicado: (2020)

The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease
por: Jia, Longfei, et al.
Publicado: (2020)

APOE-ε4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease
por: Hou, Min, et al.
Publicado: (2021)

APOE ε4, Alzheimer’s disease neuropathology and sleep disturbance, in individuals with and without dementia
por: Blackman, Jonathan, et al.
Publicado: (2022)

Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers
por: Sun, Yu, et al.
Publicado: (2019)

Identification of epigenome-wide DNA methylation differences between carriers of APOE ε4 and APOE ε2 alleles
por: Walker, Rosie M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3lhfvm9jigjq3ag5447oijdp2h